Literature DB >> 24174534

miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule-targeting drugs.

Youngmi Kim1, Deokbum Park, Hyuna Kim, Munseon Choi, Hansoo Lee, Yun Sil Lee, Jongseon Choe, Young Myeong Kim, Dooil Jeoung.   

Abstract

Cancer/testis antigen cancer-associated gene (CAGE) is known to be involved in various cellular processes, such as proliferation, cell motility, and anti-cancer drug resistance. However, the mechanism of the expression regulation of CAGE remains unknown. Target scan analysis predicted the binding of microRNA-200b (miR-200b) to CAGE promoter sequences. The expression of CAGE showed an inverse relationship with miR-200b in various cancer cell lines. miR-200b was shown to bind to the 3'-UTR of CAGE and to regulate the expression of CAGE at the transcriptional level. miR-200b also enhanced the sensitivities to microtubule-targeting drugs in vitro. miR-200b and CAGE showed opposite regulations on invasion potential and responses to microtubule-targeting drugs. Xenograft experiments showed that miR-200b had negative effects on the tumorigenic and metastatic potential of cancer cells. The effect of miR-200b on metastatic potential involved the expression regulation of CAGE by miR-200b. miR-200b decreased the tumorigenic potential of a cancer cell line resistant to microtubule-targeting drugs in a manner associated with the down-regulation of CAGE. ChIP assays showed the direct regulation of miR-200b by CAGE. CAGE enhanced the invasion potential of a cancer cell line stably expressing miR-200b. miR-200b exerted a negative regulation on tumor-induced angiogenesis. The down-regulation of CAGE led to the decreased expression of plasminogen activator inhibitor-1, a TGFβ-responsive protein involved in angiogenesis, and VEGF. CAGE mediated tumor-induced angiogenesis and was necessary for VEGF-promoted angiogenesis. Human recombinant CAGE protein displayed angiogenic potential. Thus, miR-200b and CAGE form a feedback regulatory loop and regulate the response to microtubule-targeting drugs, as well as the invasion, tumorigenic potential, and angiogenic potential.

Entities:  

Keywords:  Angiogenesis; Angiogenic Potential; Anticancer Drug; CAGE; Cancer Biology; Feedback Regulatory Loop; Invasion; MicroRNA; Tumorigenic Potential; miR-200b

Mesh:

Substances:

Year:  2013        PMID: 24174534      PMCID: PMC3868763          DOI: 10.1074/jbc.M113.502047

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs.

Authors:  Youngmi Kim; Hyunmi Park; Deokbum Park; Yun-Sil Lee; Jongseon Choe; Jang-Hee Hahn; Hansoo Lee; Young-Myeong Kim; Dooil Jeoung
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner.

Authors:  Elaine Por; Hee-Jung Byun; Eun-Ju Lee; Jeong-Hee Lim; So-Young Jung; Iha Park; Young-Myeong Kim; Doo-Il Jeoung; HanSoo Lee
Journal:  J Biol Chem       Date:  2010-03-10       Impact factor: 5.157

3.  Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels.

Authors:  Ang Li; Noriyuki Omura; Seung-Mo Hong; Audrey Vincent; Kimberly Walter; Margaret Griffith; Michael Borges; Michael Goggins
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

4.  Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.

Authors:  Olga Aprelikova; Silvia Pandolfi; Sean Tackett; Mark Ferreira; Konstantin Salnikow; Yvona Ward; John I Risinger; J Carl Barrett; John Niederhuber
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

5.  Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy.

Authors:  Anupam Basu; Gina Menicucci; Joann Maestas; Arup Das; Paul McGuire
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-14       Impact factor: 4.799

6.  miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics.

Authors:  Nadav Bar; Rivka Dikstein
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

7.  Endothelin-stimulated human B-type natriuretic peptide gene expression is mediated by Yin Yang 1 in association with histone deacetylase 2.

Authors:  Denis J Glenn; Feng Wang; Songcang Chen; Minobu Nishimoto; David G Gardner
Journal:  Hypertension       Date:  2009-01-12       Impact factor: 10.190

8.  Cathepsin G-mediated enhanced TGF-beta signaling promotes angiogenesis via upregulation of VEGF and MCP-1.

Authors:  Thomas J Wilson; Kalyan C Nannuru; Mitsuru Futakuchi; Rakesh K Singh
Journal:  Cancer Lett       Date:  2009-07-30       Impact factor: 8.679

9.  miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.

Authors:  Liana Adam; Meng Zhong; Woonyoung Choi; Wei Qi; Milena Nicoloso; Ameeta Arora; George Calin; Hua Wang; Arlene Siefker-Radtke; David McConkey; Menashe Bar-Eli; Colin Dinney
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

10.  Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1).

Authors:  Wang Rui; Feng Bing; Song Hai-Zhu; De Wei; Chen Long-Bang
Journal:  J Cell Mol Med       Date:  2009-11-09       Impact factor: 5.310

View more
  16 in total

1.  miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.

Authors:  Youngmi Kim; Hyuna Kim; Hyunmi Park; Deokbum Park; Hansoo Lee; Yun Sil Lee; Jongseon Choe; Young Myeong Kim; Dooil Jeoung
Journal:  J Biol Chem       Date:  2014-08-19       Impact factor: 5.157

2.  MicroRNA-21 controls hTERT via PTEN in human colorectal cancer cell proliferation.

Authors:  Yang Yang; Jing-Jing Yang; Hui Tao; Wei-Sen Jin
Journal:  J Physiol Biochem       Date:  2015-01-21       Impact factor: 4.158

Review 3.  microRNA-200b as a Switch for Inducible Adult Angiogenesis.

Authors:  Mithun Sinha; Subhadip Ghatak; Sashwati Roy; Chandan K Sen
Journal:  Antioxid Redox Signal       Date:  2015-05-10       Impact factor: 8.401

Review 4.  Oncogenic cancer/testis antigens: prime candidates for immunotherapy.

Authors:  Morten F Gjerstorff; Mads H Andersen; Henrik J Ditzel
Journal:  Oncotarget       Date:  2015-06-30

5.  miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3.

Authors:  Youngmi Kim; Hyuna Kim; Deokbum Park; Dooil Jeoung
Journal:  Mol Cells       Date:  2015-05-22       Impact factor: 5.034

6.  miR-30a Regulates the Expression of CAGE and p53 and Regulates the Response to Anti-Cancer Drugs.

Authors:  Deokbum Park; Hyuna Kim; Youngmi Kim; Dooil Jeoung
Journal:  Mol Cells       Date:  2016-02-25       Impact factor: 5.034

7.  miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.

Authors:  Youngmi Kim; Hyuna Kim; Deokbum Park; Minho Han; Hansoo Lee; Yun Sil Lee; Jongseon Choe; Young Myeong Kim; Dooil Jeoung
Journal:  Oncotarget       Date:  2016-03-01

8.  DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2.

Authors:  Youngmi Kim; Minjeong Yeon; Dooil Jeoung
Journal:  Mol Cells       Date:  2017-05-02       Impact factor: 5.034

9.  DDX53 Promotes Cancer Stem Cell-Like Properties and Autophagy.

Authors:  Hyuna Kim; Youngmi Kim; Dooil Jeoung
Journal:  Mol Cells       Date:  2017-01-26       Impact factor: 5.034

10.  Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs.

Authors:  Hyuna Kim; Youngmi Kim; Hyeonjung Goh; Dooil Jeoung
Journal:  Mol Cells       Date:  2016-02-16       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.